Mauna Kea Technologies Winner of “Best New Technology Solution – Oncology” MedTech Breakthrough Award
Prestigious international program recognizes standout digital health & medical technology products and companies
2024 awards program included more than 4,500 nominations from all around the world
PARIS & BOSTON–(BUSINESS WIRE)–Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has been selected as the winner of the “Best New Technology Solution – Oncology” award in the 8th annual MedTech Breakthrough Awards program. MedTech Breakthrough is an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market, and the 2024 awards program included more than 4,500 nominations from all around the world.
This award recognizes Mauna Kea’s critical role in delivering meaningful MedTech product innovation across a wide range of interventional oncology indications, including gastroenterology, pulmonology and uro-oncology, using its next-generation proprietary in vivo cellular imaging platform, Cellvizio®. The platform allows physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. Physicians are able to use the information provided by Cellvizio® to accurately identify and risk stratify neoplastic tissue and create personalized patient treatment plans, generating significantly more favorable clinical and economic outcomes.
“We are honored to be recognized by MedTech Breakthrough for our newest product innovation and ongoing commitment to advancing MedTech for interventionalists worldwide,” said Sacha Loiseau, Ph.D., Founder, Chairman and Chief Executive Officer of Mauna Kea Technologies. “Cancer remains a leading cause of death worldwide, and many cancers can be cured if detected early and treated effectively. Our next-generation Cellvizio platform continues to push the boundaries of what is possible with real-time cellular imaging in addressing the challenges of diagnosing and treating a wide range of pre-cancerous and cancerous conditions, leading to improved patient outcomes.”
***
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies’ financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies’ 2023 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2024, which is available on the Company’s website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
Contacts
Mauna Kea Technologies
investors@maunakeatech.com
NewCap – Investor Relations
Aurélie Manavarere / Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu
